Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | APAF1 | O14727 | 1/20 | 0.38 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8621288 | 0.81 | ALDH1A1 (0.44) | MMECYP2D6SRCLMNAMAPK1 | |
| SCHEMBL8621292 | 0.81 | ALDH1A1 (0.44) | MMECYP2D6SRCLMNAMAPK1 | |
| SCHEMBL29001941 | 0.81 | ALDH1A1 (0.44) | MMECYP2D6SRCLMNAMAPK1 | |
| SCHEMBL28700643 | 0.80 | LMNA (0.45) | MMECYP2D6SRCLMNAMAPK1 | |
| SCHEMBL594168 | 0.73 | GSR (0.44) | MMECYP2D6SRCNAALAD2 | |
| SCHEMBL8575470 | 0.71 | TGFBR1 (0.58) | MMETGFBR1NAALAD2 | |
| SCHEMBL7222907 | 0.70 | MME (0.68) | MMEACE2 | |
| SCHEMBL344919 | 0.69 | MME (0.45) | MMELMNAMAPK1POLB | |
| SCHEMBL344918 | 0.69 | MME (0.45) | MMELMNAMAPK1POLB | |
| SCHEMBL3488827 | 0.69 | MME (0.45) | MMELMNAMAPK1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007137080-A2 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2007-11-29 | — | — | WO | disclosed |